These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 6135099

  • 1. Activities of newer quinolones against Legionella group organisms.
    Greenwood D, Laverick A.
    Lancet; 1983 Jul 30; 2(8344):279-80. PubMed ID: 6135099
    [No Abstract] [Full Text] [Related]

  • 2. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr 30; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 3. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL, van der Ros-van de Repe J, van Veldhuizen G.
    Antimicrob Agents Chemother; 1983 Aug 30; 24(2):302-4. PubMed ID: 6227281
    [Abstract] [Full Text] [Related]

  • 4. [Antibacterial activity in vitro of 10 quinolones against 20 strains of Legionella pneumophila].
    Deforges L, Fournet MP, Soussy CJ, Duval J.
    Pathol Biol (Paris); 1986 Jun 30; 34(5 Pt 2):631-3. PubMed ID: 3534757
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ciprofloxacin and norfloxacin against Gardnerella vaginalis.
    Machka K.
    Eur J Clin Microbiol; 1984 Aug 30; 3(4):374. PubMed ID: 6237906
    [No Abstract] [Full Text] [Related]

  • 6. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
    Ridgway GL, Mumtaz G, Gabriel FG, Oriel JD.
    Eur J Clin Microbiol; 1984 Aug 30; 3(4):344-6. PubMed ID: 6237903
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
    Gay JD, DeYoung DR, Roberts GD.
    Antimicrob Agents Chemother; 1984 Jul 30; 26(1):94-6. PubMed ID: 6236748
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of conjugal transfer by new quinolinic compounds.
    Oliva B, Selan L, Ravagnan G, Renzini G.
    Chemioterapia; 1985 Jun 30; 4(3):199-201. PubMed ID: 3161641
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens.
    Diez-Enciso M, Mas-Jimenez G, Velasco-Cerrudo A, Gutierrez-Altes A.
    Eur J Clin Microbiol; 1984 Aug 30; 3(4):367. PubMed ID: 6237905
    [No Abstract] [Full Text] [Related]

  • 10. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH.
    Chemotherapy; 1985 Aug 30; 31(1):34-9. PubMed ID: 3156026
    [Abstract] [Full Text] [Related]

  • 11. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM, Baltch AL, Smith RP.
    J Antimicrob Chemother; 1986 May 30; 17(5):623-8. PubMed ID: 2941401
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
    Peeters M, Van Dyck E, Piot P.
    Antimicrob Agents Chemother; 1984 Oct 30; 26(4):608-9. PubMed ID: 6240224
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of ciprofloxacin against group JK corynebacteria.
    Machka K, Balg H.
    Eur J Clin Microbiol; 1984 Aug 30; 3(4):375. PubMed ID: 6237907
    [No Abstract] [Full Text] [Related]

  • 14. Activities of newer quinolones against legionella group organisms.
    Fallon RJ.
    Lancet; 1983 Aug 27; 2(8348):525. PubMed ID: 6136688
    [No Abstract] [Full Text] [Related]

  • 15. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov 27; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW, Muytjens HL.
    Antimicrob Agents Chemother; 1984 Jan 27; 25(1):123-4. PubMed ID: 6230988
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, Sommers HM.
    Antimicrob Agents Chemother; 1984 May 27; 25(5):633-7. PubMed ID: 6233935
    [Abstract] [Full Text] [Related]

  • 18. Comparative in-vitro activity of quinolone carboxylic acids against Proteeae.
    Hawkey PM, Hawkey CA.
    J Antimicrob Chemother; 1984 Nov 27; 14(5):485-9. PubMed ID: 6511707
    [Abstract] [Full Text] [Related]

  • 19. Mutational resistance to 4-quinolone antibacterial agents.
    Smith JT.
    Eur J Clin Microbiol; 1984 Aug 27; 3(4):347-50. PubMed ID: 6237904
    [Abstract] [Full Text] [Related]

  • 20. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL, Jones RN.
    Antimicrob Agents Chemother; 1984 Jun 27; 25(6):775-7. PubMed ID: 6234858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.